Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
BIO-RAD LABORATORIES, INC. incurred revolving credit of $200,000,000 with Wells Fargo Bank, National Association, as agent at Term SOFR plus 0.10% per annum plus the Applicable Margin maturing February 13, 2029.
- Instrument
- revolving credit
- Principal
- $200,000,000
- Counterparty
- Wells Fargo Bank, National Association, as agent
- Rate
- Term SOFR plus 0.10% per annum plus the Applicable Margin
- Maturity
- February 13, 2029
- Event
- incurrence
Exact text from the filing
all commitments thereunder. No penalties were due in connection with such repayments. Borrowings under the Revolving Credit Agreement are permitted up to a maximum amount of $200,000,000 on a revolving basis, including up to $25,000,000 of letters of credit. Borrowings of revolving loans may be made, at the Borrowers’ election, in U.S. dollars, Euros, Swiss
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Norman Schwartz was appointed as principal financial officer at BIO-RAD LABORATORIES, INC..
- Action
- appointed
- Role
- principal financial officer
Exact text from the filing
On February 9, 2024, the Company’s board of directors appointed Norman Schwartz, the Company’s President and Chief Executive Officer and the Chairman of the Board, as the Company’s principal financial officer until a permanent replacement for Mr. Daskal has been appointed.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ilan Daskal resigned as Executive Vice-President, Chief Financial Officer at BIO-RAD LABORATORIES, INC..
- Action
- resigned
- Role
- Executive Vice-President, Chief Financial Officer
Exact text from the filing
Ilan Daskal resigned from his position as the Company’s Executive Vice-President, Chief Financial Officer and the Company’s principal financial officer in order to pursue other opportunities.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
BIO-RAD LABORATORIES, INC. entered into Revolving Credit Agreement with Wells Fargo Bank, National Association, as agent valued at $200,000,000 (effective 2024-02-13).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Wells Fargo Bank, National Association, as agent
- Value
- $200,000,000
- Effective
- 2024-02-13
Exact text from the filing
Bio-Rad Laboratories, Inc. (the “Company”) entered into a Credit Agreement dated as of February 13, 2024 (the “Revolving Credit Agreement”), by and among the Company, Bio-Rad Europe GmbH, Bio-Rad IHC Europe GmbH and Bio-Rad Laboratories (Singapore) Pte Ltd (collectively, the “Borrowers”), the lenders referred to therein, and Wells Fargo Bank, National Association, as agent.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
BIO-RAD LABORATORIES, INC. terminated Previous Revolving Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., HSBC Bank USA, National Association, and MUFG Bank, Ltd. as co-syndication agents, and Citibank, N.A. and Wells Fargo Bank, National Association as co-documentation agents (effective 2024-02-14).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., HSBC Bank USA, National Association, and MUFG Bank, Ltd. as co-syndication agents, and Citibank, N.A. and Wells Fargo Bank, National Association as co-documentation agents
- Effective
- 2024-02-14
Exact text from the filing
The Company repaid in full all outstanding obligations under the Previous Revolving Credit Agreement on February 14, 2024 and terminated all commitments thereunder.
View on SEC.gov